Chronic hepatitis B: who to treat and which choice of treatment?

References

• Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology43, S173–S181 (2006).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol.48, 335–352 (2008).
   PubMed Web of Science ®Google Scholar
• Fattovich G. Natural history and prognosis of hepatitis B. Semin. Liver Dis.23, 47–58 (2003).
   PubMed Web of Science ®Google Scholar
• Manno M, Cammà C, Schepis et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology127, 756–763 (2004).
   PubMed Web of Science ®Google Scholar
• Hadziyannis S, Papatheodoridis GV. Hepatitis B e antigen negative chronic hepatitis: natural history and treatment. Semin. Liver Dis.26, 130–141 (2006).
   PubMed Web of Science ®Google Scholar
• Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology126, 1750–1758 (2004).
   PubMed Web of Science ®Google Scholar
• Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann. Intern. Med.147, 58–61 (2007).
   PubMed Web of Science ®Google Scholar
• Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J. Hepatol.46, 734–742 (2007).
   PubMed Web of Science ®Google Scholar
• Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med.334, 1422–1427 (1996).
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351, 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antivir. Res.64, 1–15 (2004).
   PubMed Web of Science ®Google Scholar
• Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med.119, 312–323 (1993).
   PubMed Web of Science ®Google Scholar
• Craxì A, Di Bona D, Camma C. Interferon-α for HBeAg-positive chronic hepatitis B. J. Hepatol.39, S99–S105 (2003).
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.352, 2682–2695 (2005).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.351, 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med.339, 61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med.341, 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Lampertico P, Marzano A et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology40, 883–891 (2004).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Seto WK, Chow DH et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther.12, 1295–1303 (2007).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med.348, 808–816 (2003).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med.348, 800–807 (2003).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology42, 1414–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med.352, 2673–2681 (2005).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology131, 1743–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology133, 1445–1451 (2007).
   PubMed Web of Science ®Google Scholar
• Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology45, 307–313 (2007).
   PubMed Web of Science ®Google Scholar
• Qi X, Xiong S, Yang H et al.In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther.12, 355–362 (2007).
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.354, 1011–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.354, 1001–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology130, 2039–2049 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology48, 99–108 (2008).
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology44, 1656–1665 (2006).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Pokornowsky KA, Rose RE et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B resistance Hepatolology (2009) (In Press).
   Google Scholar
• Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology129, 528–536 (2005).
   PubMed Web of Science ®Google Scholar
• Chan HL, Heathcote EJ, Marcellin P et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med.147, 745–754 (2007).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology136(2), 486–495 (2009).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med.359, 2442–2455 (2008).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Dusheiko G, Hatzakis A et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology134, 405–415 (2008).
   PubMed Web of Science ®Google Scholar
• Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med.137, 1–10 (2002).
   PubMed Web of Science ®Google Scholar
• Lai M, Hyatt BJ, Nasser I et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J. Hepatol.47, 760–767 (2007).
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J. Hepatol.50, 227–242 (2009).
   PubMed Web of Science ®Google Scholar
• Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig. Liver Dis.40, 603–617 (2008).
   PubMedGoogle Scholar
• Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol.6, 1315–1341 (2008).
   PubMed Web of Science ®Google Scholar
• Moucari R, Mackiewicz V, Lada O et al Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon α-2a in HBeAg-negative patients. Hepatology (2009) (In Press).
   Google Scholar
• Wilt TJ, Shamliyan T, Shaukat A et al. Management of chronic hepatitis B. Evidence report/technology assessment No. 174. Prepared by the Minnesota evidence-based practice center under contract no. 290-202-0009). AHRQ Publication No. 09-E002. Agency for Healthcare Research and Quality, Rockville, MD, USA (2008).
   Google Scholar
• Janssen HL, Gerken G, Carreno V et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology30, 238–243 (1999).
   PubMed Web of Science ®Google Scholar
• Chan HL, Wang H, Niu J et al. Two-year lamivudine treatment for hepatitis B e antigen negative chronic hepatitis B: a double-blind, placebo controlled trial. Antivir. Ther.12, 345–353 (2007).
   PubMed Web of Science ®Google Scholar
• Schiff ER, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen positive chronic hepatitis B in interferon nonresponders. J. Hepatol.38, 818–826 (2003).
   PubMed Web of Science ®Google Scholar
• Akarca US, Ersoz G, Gunsar F et al. Interferon lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir. Ther.9, 325–334 (2004).
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet365, 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg positive chronic hepatitis B. Gastroenterology133, 1437–1444 (2007).
   PubMed Web of Science ®Google Scholar
• Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology126, 91–101 (2004).
   PubMed Web of Science ®Google Scholar
• Barbaro G, Zechini F, Pellicelli AM et al. Long-term efficacy of interferon α-2b and lamivudine in combination compared with lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J. Hepatol.35, 406–411 (2001).
   PubMed Web of Science ®Google Scholar
• Economou M, Manolakopoulos S, Trikalinos TA et al. Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J. Gastroenterol.11, 5882–5887 (2005).
   PubMed Web of Science ®Google Scholar
• Flink HJ, van Zonneveld M, Hansen BE et al. Treatment with peg-interferon α-2b for HBeAg positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol.101, 297–303 (2006).
   PubMed Web of Science ®Google Scholar
• Ke CZ, Chen Y, Gong ZJ et al. Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment. World J. Gastroenterol.12, 4061–4063 (2006).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology119, 172–180 (2000).
   PubMed Web of Science ®Google Scholar
• Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology126, 81–90 (2004).
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao Y, Yao G et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology44, 108–116 (2006).
   PubMed Web of Science ®Google Scholar
• Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology126, 81–90 (2004).
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Fong TL, Fried MW et al. A randomized, controlled trial of recombinant α-interferon therapy for chronic hepatitis B. Am. J. Gastroenterol.88, 1887–1892 (1993).
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology36, 186–194 (2002).
   PubMed Web of Science ®Google Scholar
• Chan HL, Hui AY, Wong VW et al. Long-term follow-up of peg interferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology41, 1357–1364 (2005).
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Kumar R et al. Higher efficacy of sequential therapy with interferon-α and lamivudine combination compared with lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am. J. Gastroenterol.100, 2463–2471 (2005).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Chow DH, Tsui K et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment. Pharmacol. Ther.21, 841–849 (2005).
   PubMed Web of Science ®Google Scholar
• Buster EH, Hansen BE, Buti M et al. Peginterferon α-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology46, 388–394 (2007).
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology123, 719–727 (2002).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45, 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol.6, 1315–1341 (2008).
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Leung N, Kao J-H et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int.2, 263–283 (2008).
   PubMed Web of Science ®Google Scholar
• Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin. Liver Dis.11, 869–892 (2007).
   PubMedGoogle Scholar